Search

Your search keyword '"Pietrasanta, Daniela"' showing total 42 results
Start Over Author "Pietrasanta, Daniela"
42 results on '"Pietrasanta, Daniela"'

1. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

2. Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice

Author

Tavarozzi, Rita, primary, Zacchi, Giulia, additional, Pietrasanta, Daniela, additional, Catania, Gioacchino, additional, Castellino, Alessia, additional, Monaco, Federico, additional, Gandolfo, Carolina, additional, Rivela, Paolo, additional, Sofia, Antonella, additional, Schiena, Noemi, additional, Bertassello, Claudia, additional, Limberti, Giulia, additional, Zallio, Francesco, additional, Zanni, Manuela, additional, and Ladetto, Marco, additional

Published
2023
Full Text
View/download PDF

3. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Author

Gentile, Massimo, Martino, Enrica Antonia, Visentin, Andrea, Coscia, Marta, Reda, Gianluigi, Sportoletti, Paolo, Mauro, Francesca Romana, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Vigna, Ernesto, Mendicino, Francesco, Lucia, Eugenio, Bossio, Sabrina, Recchia, Anna Grazia, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Al-Janazreh, Hamdi, Vitale, Candida, Tripepi, Giovanni, D’Arrigo, Graziella, Angeletti, Ilaria, Bomben, Riccardo, Neri, Antonino, Cutrona, Giovanna, Fronza, Gilberto, Di Raimondo, Francesco, Gaidano, Gianluca, Cuneo, Antonio, Foà, Robin, Ferrarini, Manlio, Trentin, Livio, Gattei, Valter, and Morabito, Fortunato

Published
2020
Full Text
View/download PDF

4. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

5. S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Author

Frustaci, Anna Maria, primary, Montillo, Marco, additional, Rossi, Davide, additional, Zinzani, Pier Luigi, additional, Motta, Marina, additional, Gaidano, Gianluca, additional, Quaresmini, Giulia, additional, Scarfò, Lydia, additional, Pietrasanta, Daniela, additional, Coscia, Marta, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Cairoli, Roberto, additional, Stüssi, Georg, additional, Zucca, Emanuele, additional, Pileri, Stefano, additional, Zenz, Thorsten, additional, and Tedeschi, Alessandra, additional

Published
2023
Full Text
View/download PDF

6. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome

Author

Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra, Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023

7. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

8. The role of Bruton’s kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

Author

Catania, Gioacchino, primary, Tavarozzi, Rita, additional, Pini, Giacomo Maria, additional, Borra, Tiziana, additional, Gandolfo, Carolina, additional, Zacchi, Giulia, additional, Pietrasanta, Daniela, additional, Monaco, Federico, additional, Zanni, Manuela, additional, Lettieri, Maddalena, additional, Rivela, Paolo, additional, Zallio, Francesco, additional, and Ladetto, Marco, additional

Published
2023
Full Text
View/download PDF

9. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Author

Visentin, Andrea, Mauro, Francesca Romana, Scarfò, Lydia, Gentile, Massimo, Farina, Lucia, Reda, Gianluigi, Ferrarini, Isacco, Proietti, Giulia, Derenzini, Enrico, Cibien, Francesca, Vitale, Candida, Sanna, Alessandro, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Rigolin, Gian Matteo, Sportoletti, Paolo, Trimarco, Valentina, Cavarretta, Chiara Adele, Angotzi, Francesco, Cellini, Alessandro, Ruocco, Valeria, Zatta, Ivan, Laurenti, Luca, Molica, Stefano, Coscia, Marta, Ghia, Paolo, Foà, Robin, Cuneo, Antonio, and Trentin, Livio

Published
2023

10. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

11. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

12. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Author

Fresa, Alberto, Autore, Francesco, Piciocchi, Alfonso, Catania, Gioacchino, Visentin, Andrea, Tomasso, Annamaria, Moretti, Marina, Vitale, Candida, Chiarenza, Annalisa, Morelli, Francesca, Sportoletti, Paolo, Marasca, Roberto, Sapienza, Giuseppe, Cuccaro, Annarosa, Murru, Roberta, Sanna, Alessandro, Patti, Caterina, Angeletti, Ilaria, Coscia, Marta, Trentin, Livio, Pietrasanta, Daniela, Innocenti, Idanna, and Laurenti, Luca

Published
2022
Full Text
View/download PDF

13. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

Author

Visentin, Andrea, Mauro, Francesca Romana, Cibien, Francesca, Vitale, Candida, Reda, Gianluigi, Fresa, Alberto, Ciolli, Stefania, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Scarfò, Lydia, Sportoletti, Paolo, Pravato, Stefano, Piazza, Francesco, Coscia, Marta, Laurenti, Luca, Molica, Stefano, Foà, Robin, Cuneo, Antonio, Trentin, Livio, Laurenti, Luca (ORCID:0000-0002-8327-1396), Visentin, Andrea, Mauro, Francesca Romana, Cibien, Francesca, Vitale, Candida, Reda, Gianluigi, Fresa, Alberto, Ciolli, Stefania, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Scarfò, Lydia, Sportoletti, Paolo, Pravato, Stefano, Piazza, Francesco, Coscia, Marta, Laurenti, Luca, Molica, Stefano, Foà, Robin, Cuneo, Antonio, Trentin, Livio, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

14. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Author

Mauro, Francesca Romana, primary, Paoloni, Francesca, additional, Molica, Stefano, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Sportoletti, Paolo, additional, Marchetti, Monia, additional, Pietrasanta, Daniela, additional, Marasca, Roberto, additional, Gaidano, Gianluca, additional, Coscia, Marta, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Di Renzo, Nicola Di, additional, Ilariucci, Fiorella, additional, Liberati, Anna Marina, additional, Orsucci, Lorella, additional, Re, Francesca, additional, Tani, Monica, additional, Musuraca, Gerardo, additional, Gottardi, Daniela, additional, Zinzani, Pier Luigi, additional, Gozzetti, Alessandro, additional, Molinari, Annalia, additional, Gentile, Massimo, additional, Chiarenza, Annalisa, additional, Laurenti, Luca, additional, Varettoni, Marzia, additional, Ibatici, Adalberto, additional, Murru, Roberta, additional, Ruocco, Valeria, additional, Del Giudice, Ilaria Del, additional, De Propris, Maria Stefania De, additional, Della Starza, Irene Della, additional, Raponi, Sara, additional, Nanni, Mauro, additional, Fazi, Paola, additional, Neri, Antonino, additional, Guarini, Anna, additional, Rigolin, Gian Matteo, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

15. Continuous treatment with Ibrutinib in 100 untreated patients with TP 53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study

Author

Visentin, Andrea, primary, Mauro, Francesca Romana, additional, Cibien, Francesca, additional, Vitale, Candida, additional, Reda, Gianluigi, additional, Fresa, Alberto, additional, Ciolli, Stefania, additional, Pietrasanta, Daniela, additional, Marchetti, Monia, additional, Murru, Roberta, additional, Gentile, Massimo, additional, Rigolin, Gian Matteo, additional, Quaglia, Francesca Maria, additional, Scarfò, Lydia, additional, Sportoletti, Paolo, additional, Pravato, Stefano, additional, Piazza, Francesco, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Molica, Stefano, additional, Foà, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2021
Full Text
View/download PDF

16. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Author

Herishanu, Yair, primary, Levi, Shai, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Bairey, Osnat, additional, Del Poeta, Giovanni, additional, Ziv Baran, Tomer, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Breaster, Andrei, additional, Bronstein, Yotam, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonino, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foa, Robin, additional, Cuneo, Antonio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

17. An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)

Author

Scarfo, Lydia, primary, Albi, Elisa, additional, Quaglia, Francesca M., additional, Marasca, Roberto, additional, Sanna, Alessandro, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Gaidano, Gianluca, additional, Mannina, Donato, additional, Gentile, Massimo, additional, Patti, Caterina, additional, Reda, Gianluigi, additional, Piciocchi, Alfonso, additional, Fazi, Paola, additional, Soddu, Stefano, additional, Pietrasanta, Daniela, additional, Orsucci, Lorella, additional, Molica, Stefano, additional, Ferrario, Andrea, additional, Ferrari, Angela, additional, Sportoletti, Paolo, additional, Angeletti, Ilaria, additional, Galimberti, Sara, additional, Chiarenza, Annalisa, additional, Morelli, Francesca, additional, Mauro, Francesca, additional, Cuneo, Antonio, additional, and Ghia, Paolo, additional

Published
2021
Full Text
View/download PDF

18. Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Author

Rigolin, Gian Matteo, Frustaci, Annamaria, Piciocchi, Alfonso, Visentin, Andrea, Vitagliano, Orsola, Coscia, Marta, Farina, Lucia, Gaidano, Gianluca, Murru, Roberta, Varettoni, Marzia, Arcaini, Luca, Cibien, Francesca, Paolini, Rossella, Sportoletti, Paolo, Pietrasanta, Daniela, Molinari, Anna Lia, Quaglia, Francesca M., Laurenti, Luca, Marasca, Roberto, Marchetti, Monia, Chiarenza, Annalisa, Mauro, Francesca Romana, Perbellini, Omar, Mannina, Donato, Sancetta, Rosaria, Olivieri, Attilio, Molica, Stefano, Pane, Fabrizio, Patti, Caterina, Iliariucci, Fiorella, Gozzetti, Alessandro, Califano, Catello, Galieni, Piero, Augello, Accursio Fabio, Vallisa, Daniele, Cura, Francesca, Crea, Enrico, Fazi, Paola, Zamprogna, Giulia, Krampera, Mauro, Trentin, Livio, Ferrara, Felicetto, Gentile, Massimo, Montillo, Marco, Foà, Robin, and Cuneo, Antonio

Published
2020
Full Text
View/download PDF

19. Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘

Author

Mauro, Francesca Romana, Reda, Gianluigi, Arena, Valentina, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Laurenti, Luca, Gaidano, Gianluca, Marasca, Roberto, Orsucci, Lorella, Murru, Roberta, Stelitano, Caterina, Ilariucci, Fiorella, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfo, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Califano, Catello, Gottardi, Daniela, Liberati, Anna Marina, Pietrasanta, Daniela, Molica, Stefano, Cassin, Ramona, Visentin, Andrea, Vitale, Candida, Lapietra, Gianfranco, Della Starza, Irene, De Propris, Maria Stefania, Raponi, Sara, Nanni, Mauro, Del Giudice, Ilaria, Giuliani, Giorgia, Vignetti, Marco, Guarini, Anna, Albano, Francesco, Neri, Antonino, Cuneo, Antonio, and Foà, Robin

Published
2020
Full Text
View/download PDF

21. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report

Author

Cuneo, Antonio, primary, Rigolin, Gian Matteo, additional, Coscia, Marta, additional, Quaresmini, Giulia, additional, Scarfò, Lydia, additional, Mauro, Francesca Romana, additional, Motta, Marina, additional, Quaglia, Francesca Maria, additional, Trentin, Livio, additional, Ferrario, Andrea, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Ferrari, Angela, additional, Pietrasanta, Daniela, additional, Sportoletti, Paolo, additional, Re, Francesca, additional, De Paoli, Lorenzo, additional, Foglietta, Myriam, additional, Giordano, Annamaria, additional, Marchetti, Monia, additional, Farina, Lucia, additional, Del Poeta, Giovanni, additional, Varettoni, Marzia, additional, Chiurazzi, Federico, additional, Marasca, Roberto, additional, Malerba, Lara, additional, Ibatici, Adalberto, additional, Tisi, Maria Chiara, additional, Stefoni, Vittorio, additional, Leone, Monica, additional, Baratè, Claudia, additional, Olivieri, Jacopo, additional, Murru, Roberta, additional, Gentile, Massimo, additional, Sanna, Alessandro, additional, Gozzetti, Alessandro, additional, Gattei, Valter, additional, Gottardi, Daniela, additional, Derenzini, Enrico, additional, Levato, Luciano, additional, Orsucci, Lorella, additional, Penna, Giuseppa, additional, Chiarenza, Annalisa, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

22. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Recchia, Anna Grazia, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Olivieri, Jacopo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

23. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Cassin, Ramona, additional, D′Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Olivieri, Jacopo, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Cuneo, Antonio, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

24. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Caracciolo, Daniele, additional, Cassin, Ramona, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

25. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Cassin, Ramona, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

26. Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus

Author

Visentin, Andrea, primary, Mauro, Francesca Romana, additional, Pietrasanta, Daniela, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Ciolli, Stefania, additional, Cassin, Ramona, additional, Cibien, Francesca, additional, Sportoletti, Paolo, additional, Gentile, Massimo, additional, Rigolin, Gian Matteo, additional, Quaglia, Francesca M., additional, Murru, Roberta, additional, Gozzetti, Alessandro, additional, Molica, Stefano, additional, Marchetti, Monia, additional, Scarfo, Lydia, additional, Reda, Gianluigi, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Pizzolo, Giovanni, additional, Semenzato, Gianpietro, additional, Foà, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2020
Full Text
View/download PDF

27. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, primary, Morabito, Fortunato, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Recchia, Anna Grazia, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Fraticelli, Vincenzo, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Tripepi, Giovanni, additional, Arrigo, Graziella D’, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Rigolin, Gian Matteo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Cuneo, Antonio, additional, Foà, Robin, additional, and Gattei, Valter, additional

Published
2020
Full Text
View/download PDF

29. External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

Author

Gentile, Massimo, primary, Morabito, Fortunato, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Recchia, Anna G, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Rigolin, Gian Matteo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Cuneo, Antonio, additional, Foà, Robin, additional, and Gattei, Valter, additional

Published
2019
Full Text
View/download PDF

30. Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Author

Griggio, Valentina, primary, Vitale, Candida, additional, Salvetti, Chiara, additional, Mauro, Francesca Romana, additional, Pietrasanta, Daniela, additional, Vincelli, Iolanda Donatella, additional, Scarfo, Lydia, additional, Del Poeta, Giovanni, additional, Gaidano, Gianluca, additional, Gattei, Valter, additional, Foà, Robin, additional, Boccadoro, Mario, additional, and Coscia, Marta, additional

Published
2019
Full Text
View/download PDF

31. Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab

Author

Gentile, Massimo, primary, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Recchia, Anna G, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Fraticelli, Vincenzo Ludovico, additional, Di Prima, Alessio, additional, Tripepi, Giovanni, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Gattei, Valter, additional, and Morabito, Fortunato, additional

Published
2019
Full Text
View/download PDF

32. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.

Author

Rigolin, Gian Matteo, Cavazzini, Francesco, Piciocchi, Alfonso, Arena, Valentina, Visentin, Andrea, Reda, Gianluigi, Zamprogna, Giulia, Cibien, Francesca, Vitagliano, Orsola, Coscia, Marta, Farina, Lucia, Gaidano, Gianluca, Murru, Roberta, Varettoni, Marzia, Paolini, Rossella, Sportoletti, Paolo, Pietrasanta, Daniela, Molinari, Anna Lia, Quaglia, Francesca M., and Laurenti, Luca

Subjects
CHRONIC lymphocytic leukemia, OVERALL survival, PROGNOSIS, RITUXIMAB, SURVIVAL rate
Abstract

Because the efficacy of new drugs reported in trials may not translate into similar results when used in the real‐life, we analyzed the efficacy of idelalisib and rituximab (IR) in 149 patients with relapsed/refractory chronic lymphocytic leukemia treated at 34 GIMEMA centers. Median progression‐free survival (PFS) and overall survival were 22.9 and 44.5 months, respectively; performance status (PS) ≥2 and ≥3 previous lines of therapy were associated with shorter PFS and overall survival (OS). 48% of patients were on treatment at 12 months; the experience of the centers (≥5 treated patients) and PS 0–1 were associated with a significantly longer treatment duration (p = 0.015 and p = 0.002, respectively). TP53 disruption had no prognostic significance. The overall response rate to subsequent treatment was 49.2%, with median OS of 15.5 months and not reached in patients who discontinued, respectively, for progression and for toxicity (p < 0.01). Treatment breaks ≥14 days were recorded in 96% of patients and adverse events mirrored those reported in trials. In conclusion, this real‐life analysis showed that IR treatment duration was longer at experienced centers, that the ECOG PS and ≥3 lines of previous therapy are strong prognostic factor and that the overall outcome with this regimen was superimposable to that reported in a randomized trial. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Author

Griggio, Valentina, primary, Vitale, Candida, additional, Todaro, Maria, additional, Mauro, Francesca Romana, additional, Salvetti, Chiara, additional, Pietrasanta, Daniela, additional, Vincelli, Iolanda Donatella, additional, Scarfo, Lydia, additional, Del Poeta, Giovanni, additional, Gaidano, Gianluca, additional, Gattei, Valter, additional, Foà, Robin, additional, Boccadoro, Mario, additional, and Coscia, Marta, additional

Published
2018
Full Text
View/download PDF

34. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Author

Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stüssi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023
Full Text
View/download PDF

35. Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib

Author

Catania, Gioacchino, primary, Monaco, Federico, additional, Pini, Massimo, additional, Corsetti, Maria Teresa, additional, Salvio, Michela, additional, Trincheri, Nicol, additional, Zallio, Francesco, additional, Pietrasanta, Daniela, additional, Baraldi, Anna, additional, Lorella, Depaoli, additional, Flavia, Salvi, additional, and Ladetto, Marco, additional

Published
2014
Full Text
View/download PDF

36. Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C

Author

Corsetti, Maria Teresa, primary, Salvi, Flavia, primary, Perticone, Sonia, primary, Allione, Bernardino, primary, Baraldi, Anna, primary, Bellora, Alessandro, primary, De Paoli, Lorella, primary, Gatto, Simona, primary, Pietrasanta, Daniela, primary, Primon, Valeria, primary, Pini, Massimo, primary, Tonso, Anna, primary, Musi, Marco, primary, Ciravegna, Giorgio, primary, Zallio, Francesco, primary, and Levis, Alessandro, primary

Published
2008
Full Text
View/download PDF

38. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Author

Mauro, Francesca Romana, Paoloni, Francesca, Molica, Stefano, Reda, Gianluigi, Trentin, Livio, Sportoletti, Paolo, Marchetti, Monia, Pietrasanta, Daniela, Marasca, Roberto, Gaidano, Gianluca, Coscia, Marta, Stelitano, Caterina, Mannina, Donato, Di Renzo, Nicola, Ilariucci, Fiorella, Liberati, Anna Marina, Orsucci, Lorella, Re, Francesca, Tani, Monica, and Musuraca, Gerardo

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RITUXIMAB, CHRONIC lymphocytic leukemia, DISEASE progression, COMBINATION drug therapy, CLINICAL trials, ANTINEOPLASTIC agents, ADVERSE health care events, PATIENT safety
Abstract

Simple Summary: This prospective, multicenter study aimed to investigate the efficacy and safety of a front-line treatment with the ibrutinib and rituximab combination in 146 unfit patients with chronic lymphocytic leukemia (CLL). We observed an OR, CR, and 48-month PFS rates of 87%, 22.6%, and 77%, respectively. Responses with undetectable MRD were observed in 6.2% of all patients and 27% of CR patients. TP53 disruption and B-symptoms revealed a significant and independent impact on PFS. The 48-month cumulative treatment discontinuation rate due to adverse events in this patient population was 29.1%. It was significantly higher in male patients, in patients aged ≥70 years, and in those managed at centers that enrolled less than five patients. In conclusion, the ibrutinib and rituximab combination was an effective front-line treatment for unfit patients with CLL. However, a high rate of treatment discontinuations due to adverse events was observed in this unfit population. The GIMEMA group investigated the efficacy, safety, and rates of discontinuations of the ibrutinib and rituximab regimen in previously untreated and unfit patients with chronic lymphocytic leukemia (CLL). Treatment consisted of ibrutinib, 420 mg daily, and until disease progression, and rituximab (375 mg/sqm, given weekly on week 1–4 of month 1 and day 1 of months 2–6). This study included 146 patients with a median age of 73 years, with IGHV unmutated in 56.9% and TP53 disrupted in 22.2%. The OR, CR, and 48-month PFS rates were 87%, 22.6%, and 77%, respectively. Responses with undetectable MRD were observed in 6.2% of all patients and 27% of CR patients. TP53 disruption (HR 2.47; p = 0.03) and B-symptoms (HR 2.91; p = 0.02) showed a significant and independent impact on PFS. The 48-month cumulative rates of treatment discontinuations due to disease progression (DP) or adverse events (AEs) were 5.6% and 29.1%, respectively. AEs leading more frequently to treatment discontinuation were atrial fibrillation in 8% of patients, infections in 8%, and non-skin cancers in 6%. Discontinuation rates due to AEs were higher in male patients (HR: 0.46; p = 0.05), patients aged ≥70 years (HR 5.43, p = 0.0017), and were managed at centers that enrolled <5 patients (HR 5.1, p = 0.04). Patients who discontinued ibrutinib due to an AE showed a 24-month next treatment-free survival rate of 63%. In conclusion, ibrutinib and rituximab combination was an effective front-line treatment with sustained disease control in more than half of unfit patients with CLL. Careful monitoring is recommended to prevent and manage AEs in this patient population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.

Author

Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, and Trentin L

Subjects
Humans, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Sulfonamides therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Tumor Suppressor Protein p53 genetics, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Antineoplastic Agents therapeutic use
Published
2023
Full Text
View/download PDF

40. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.

Author

Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O, Del Principe MI, Fineman R, Mauro FR, Gutwein O, Reda G, Ruchlemer R, Sportoletti P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchetto A, Bomben R, Olivieri J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cuneo A, Perry C, Gattei V, Gentile M, and Herishanu Y

Subjects
Humans, Rituximab therapeutic use, Cyclophosphamide therapeutic use, Vidarabine therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2023
Full Text
View/download PDF

41. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.

Author

Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, and Trentin L

Subjects
Adenine administration & dosage, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Adenine analogs & derivatives, Gene Deletion, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Piperidines administration & dosage, Tumor Suppressor Protein p53 genetics
Published
2022
Full Text
View/download PDF

42. High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).

Author

Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, Angelucci E, Re F, Liberati AM, Tedeschi A, Reda G, Pietrasanta D, Gozzetti A, Battistini R, Del Poeta G, Musolino C, Nanni M, Piciocchi A, Vignetti M, Neri A, Albano F, Cuneo A, Del Giudice I, Della Starza I, De Propris MS, Raponi S, Guarini AR, and Foà R

Subjects
Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide therapeutic use, Humans, Rituximab therapeutic use, Treatment Outcome, Vidarabine analogs & derivatives, Vidarabine therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results